Evolus, Inc. reaffirmed revenue guidance for full year 2022. For the period, based on its year-to-date performance and confidence in a resilient and fundamentally strong aesthetic neurotoxin market, the company continues to believe it can achieve the upper end of its full-year sales guidance range of $143 million to $150 million. This assumes a minimal contribution from international markets.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.16 USD | -1.94% | +3.05% | +24.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.98% | 840M | |
+37.78% | 705B | |
+32.82% | 583B | |
-3.51% | 364B | |
+19.94% | 332B | |
+5.14% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+9.32% | 169B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022